Contraline
Summary active Updated Jun 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Contraline is a Charlottesville, Virginia-based clinical-stage biopharmaceutical company developing novel male contraceptives 12. The company is advancing both hormonal and non-hormonal approaches to expand contraceptive options for men and couples globally 1. Its lead program, NES/T Gel, is an investigational daily hormonal reversible male contraceptive, while ADAM is an investigational long-lasting non-hormonal reversible contraceptive currently in clinical development 12.
The NES/T program recently completed a global Phase 2b trial enrolling 462 couples, with Phase 3 expected to begin in 2027 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-02 | Series B | $92.5M | BVF Partners, RA Capital Management | GV, Lumira Ventures, Invus 123 |
In conjunction with the closing of the Series B financing, Iris van Alderwerelt van Rosenburgh of BVF Partners joined Contraline’s Board of Directors 12.
What Investors Say
No independently sourced investor quotes found at this time beyond press release boilerplate.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
“Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development,” BioSpace, June 2, 2026, accessed June 2026. https://www.biospace.com/press-releases/contraline-announces-92-5-million-series-b-financing-to-advance-nes-t-male-contraceptive-into-late-stage-development↩↩↩↩↩↩
-
“Lumira Announces New Fund V Investment with Contraline’s $92.5 Million Series B Financing,” Lumira Ventures, June 2, 2026, accessed June 2026. https://www.lumiraventures.com/news/lumira-announces-new-fund-v-investment-with-contralines-92-5-million-series-b-financing-to-advance-nes-t-male-contraceptive-into-late-stage-development/↩↩↩↩
-
“Wilson Sonsini Advises BVF Partners on IP Matters Related to Contraline’s $92.5 Million Series B,” Wilson Sonsini, June 2026, accessed June 2026. https://www.wsgr.com/en/insights/wilson-sonsini-advises-bvf-partners-on-ip-matters-related-to-contralines-dollar925-million-series-b.html↩